Рубрики:
The results of the two phases of the clinical trial of Avifavir for coronavirus treatment were presented at the “COVID-19: Pandemic of the XXI Century” International Congress held in Ufa on November 13–14. More than 3,500 experts from 8 countries (Russia, China, USA, Germany, Uzbekistan, Kazakhstan, Tajikistan, and Ukraine) took part in the Congress.The reports […]
Рубрики:
Chromis (Russia), a joint venture of the ChemRar Group and the Russian Direct Investment Fund (RDIF), and its partner Viriom Inc., a San Diego CA-based biotech reported a summary of the multicenter, open-labeled, efficacy and safety study of Avifavir (favipiravir) in patients with COVID-19 at the Conference on Retroviruses and Opportunistic Infections CROI2021. Background: Favipiravir […]
Рубрики:
On Friday, April 2, 2021, the head of RDIF Kirill Dmitriev at a meeting with Russian President V.V. Putin announced the success of the world’s first drug, Avifavir, with direct antiviral action for the treatment of COVID-19, which was developed and produced by the ChemRar group of companies with the support of RDIF and is […]
Рубрики:
Russian drug with proven clinical efficacy against coronavirus registered in Indonesia Avifavir became the world’s first favipiravir-based drug approved for the treatment of coronavirus, and the first drug registered in Russia against coronavirus Moscow, March 24, 2021 — The Russian Direct Investment Fund (RDIF), the sovereign wealth fund of the Russian Federation, and the ChemRar […]